CybeRelease: (OTC: CCRC) Expands Their Laboratory Capability
(CybeRelease, May 2, 2007) - Lake Harmony, PA - Clinicares Inc. (OTC PK: CCRC) announced that they have signed the purchasing contract for a laboratory located in Changjeon-dong, Seodaemun-Gu in Seoul, Korea.
The laboratory will be used to expand their products including their specialized DNA gene business in the world markets. Songmoon Hong, CEO of Clinicares, Inc., stated, “We will have a great opportunity of expanding our planned business as a result of this acquisition.”
Micro Roller and Peptide Product line:
With the conventional application of creams, gels or lotions only a fraction (less than 0.5%) of their active substances can penetrate the epidermal barrier (99.5% is lost). The upper skin layer (epidermis) consists of several layers and their structure is like a brick wall.
The Clinicares Micro Roller, studded with nearly 200 extremely fine needles of medical grade stainless steel with a tip length of 0.2mm, is the latest revolutionary cosmeceutical tool in skin care treatments. When applied to the surface of the skin, it creates deep micro channels in the layer of dead cells that normally protects the skin. These enable the active ingredients of peptide-based products to penetrate more deeply and in greater quantities than simply applying the preparation to the surface.
The “Soft” Alternative for all Common Laser & Peeling Methods:
CTS (Clinicares Treatment Solutions) is a procedure, which stimulates the skin to produce a new collagen formation, thereby reducing wrinkles and improving skin texture. Clinicares Micro Roller is used to produce many microscopic channels in the skin, which stimulate your own body to produce new collagen. These channels improve (1000 times) the penetration of the highest concentration of peptides, vitamin creams, or any other liposomal serums. The Clinicares’ peptide products, especially formulated to work with the Clinicares Micro Roller, stimulate skin renewal, which allows the skin to appear fresher, younger and with dramatically reduced fine lines and wrinkles. Clinicares Treatment Solutions (CTS) are longer lasting compared to artificial injected collagen.
To read the complete release, go to http://biz.yahoo.com/iw/070502/0247271.html
For a Free Newsletter, go to http://www.OTCReporter.com
CybeRelease Gainers are Nabi Biopharmaceuticals (Nasdaq: NABI), Angiotech Pharmaceuticals, Inc. (Nasdaq: ANPI), TTM Technologies, Inc. (Nasdaq: TTMI), United Online, Inc. (Nasdaq: UNTD), Pain Therapeutics (Nasdaq: PTIE), TeleCommunication Systems, Inc. (Nasdaq: TSYS), InterVoice Inc. (Nasdaq: INTV) and Interactive Intelligence, Inc. (Nasdaq: ININ).
CybeRelease Decliners are Neurochem Inc. (Nasdaq: NRMX), Cognizant Technology Solutions Corporation (Nasdaq: CTSH), Motive, Inc. (Nasdaq: MOTVE), Sohu.com Inc. (Nasdaq: SOHU), Acusphere, Inc. (Nasdaq: ACUS), CollaGenex Pharmaceuticals, Inc. (Nasdaq: CGPI), Sinclair Broadcast Group, Inc. (Nasdaq: SBGI) and Epicor Software Corporation (Nasdaq: EPIC).
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for informational purposes only and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.
- Contact Information
- C. P. Barry
- Media Contact
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.